Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab versus placebo in primary progressive multiple sclerosis with focus on upper limb function
NL-OMON48188Phase 3Withdrawn
- Sponsor
- Roche
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) comparing Ocrevus with Placebo (2 arms). Primary endpoint: Upper limb disability progression confirmed for at least 12 weeks. Planned start Jul 2019; status: withdrawn.
02
Drugs
ocrelizumab
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NL-OMON48188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48188.